NCT06162585View on ClinicalTrials.gov

Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study

Active, not recruitingOBSERVATIONAL
Enrollment

18

Participants

Timeline

Start Date

December 8, 2023

Primary Completion Date

July 31, 2027

Study Completion Date

September 30, 2027

Conditions
Retinitis PigmentosaRetinitisRetinal DiseasesEye DiseasesEye Diseases, HereditaryRetinal DystrophiesRetinal Degeneration
Interventions
BIOLOGICAL

Gene Therapy product-MCO-010

Safety evaluation to monitor long term effects of previously injected MCO-010 in RP patients

Trial Locations (6)

32503

Nanoscope Clinical Site, Pensacola

58103

Nanoscope Clinical Site, Fargo

77030

Nanoscope Clinical Site, Houston

78503

Nanoscope Clinical Site, McAllen

90211

Nanoscope Clinical Site, Beverly Hills

00612

Nanoscope Clinical Site, Arecibo

Sponsors
All Listed Sponsors
lead

Nanoscope Therapeutics Inc.

INDUSTRY

NCT06162585 - Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study | Biotech Hunter | Biotech Hunter